Business
Aligos Therapeutics to Present Data on pan-Coronavirus Protease Inhibitors for the Treatment of COVID-19 at Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference, to be Held October 17-20, 2022 in Boston, MA
Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023 SOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"Aligos’ pan-Coronavirus inhibitor, ALG-097558, is on track to begin first clinical studies in 1H 2023\nSOUTH SAN FRANCISCO, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the Company will make an oral presentation at the Cambridge Healthtech Institute’s 20th Annual Discovery on Target Conference being held October 17-20, 2022 in Boston, MA. In the presentation, Aligos will review its progress towards the development of broadly-acting, orally available small molecule protease inhibitors to address COVID-19, regardless of the strain. “While the new vaccines and therapeutics for COVID-19 have been very important, there is a need for more effective treatment and the continued emergence of new, dominant SARS-CoV-2 variants highlights the need for therapies that are effective regardless of the strain,” said Lawrence Blatt, PhD, MBA, CEO and Chairman and Co-Founder of Aligos. “Aligos is developing a small molecule, orally-available potential treatment for COVID-19 designed inhibit the highly conserved 3CL protease with strong potency and broad activity against a diverse range of coronaviruses, with a high barrier to resistance. We are pleased to have an opportunity to share an update on this program as we progress towards the first clinical study for our lead candidate, ALG-097558, expected to be initiated in the first half of 2023.” Title: Oral 3CL-Protease Inhibitors for Treating Coronaviral InfectionsPresenter: Koen Vandyck, Ph.D., Senior Director, Medicinal ChemistryDate/time: Thursday, October 20, 2022, 8:00 a.m. ET Rapid evolution of new SARS-CoV-2 variants and the presence of multiple other coronaviruses indicate the need for broadly acting antivirals across all coronaviruses. The SARS-CoV-2 3CL protease (3CLpro) is a clinically validated target and is conserved across coronaviruses. Aligos will review the discovery efforts towards oral pan-coronaviral 3CLpro inhibitors, culminating in the discovery and advancement of ALG-097558. About Aligos Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections ...